TWiV 1058: Clinical update with Dr. Daniel Griffin
Episode

TWiV 1058: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy, duration of SARS-CoV-2 culturable virus shedding in children, prescribing outcomes in outpatients treated with nirmatrelvir–ritonavir for COVID-19 in an interdisciplinary community clinic, Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients, optimal duration of systemic corticosteroids in COVID-19 treatment, association between Guillain-Barré syndrome and COVID-19 infection and vaccination, SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration, Transplanting candidates with COVID-19, and favorable experience of transplant strategy including liver grafts from COVID-19 donors. Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Routine vaccination coverage (CDC) Outbreak of invasive Group A Streptococcus in children (PIDS) Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 (Nature) Outcomes of SARS-CoV-2 omicron variant infections compared with seasonal influenza and RSV infections in adults (CID) Remdesivir is associated with reduced mortality in COVID-19 patients requiring oxygen (OFID) Effectiveness of nirmatrelvir/ritonavir against the development of Post–COVID-19 conditions among U.S. veterans (AIM) Contribute to our MicrobeTV fundraiser at PWB Letters read on TWiV 1058 Dr. Griffin's COVID treatment summary ( pdf ) Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Community discussion